Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Thursday, August 5, 2021. Management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company's fina

Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced executive changes as part of its strategy to position the company for long-term commercial success, including the anticipated closing of the Strongbridge Biopharma plc acquisition and evolution to a more commercially driven company. Barry Deutsch, Chie

Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success

Xeris Pharmaceuticals Inc (NASDAQ: XERS) has entered into an exclusive agreement with Tetris Pharma Limited to commercialize Ogluo in the European Economic Area, the U.K., and Switzerland. Ogluo is indicated to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus.

Xeris Pharma, Tetris Ink Commercialization Pact For Ogluo In Europe

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced an exclusive agreement with Tetris Pharma Limited (“Tetris”) for the commercialization of Ogluo® in the European Economic Area, United Kingdom, and Switzerland (the “Territory”) for the treatment of severe hypoglycaemia in adults, adolescents, and chil

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

Aditxt Inc

Sphere 3D

Vinco Ventures

Globalstar

Gran Tierra Energy

Luokung Technology Corp

MediciNova

New Gold

Pieris Pharma

Qudian

Transocean

Tellurian

US Well Services

Uxin Ltd - ADR

These penny stocks are trending right now, here's why The post Best Penny Stocks to Buy Right Now? 15 To Watch In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 15 To Watch In July

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options

XERS stock could very well be the next stock to get the short squeeze treatment, even without a r/WallStreetBets co-sign. The post Get Ready for a XERS Stock Squeeze!

Get Ready for a XERS Stock Squeeze! Why One Analyst Thinks Xeris Could Be the Next AMC

Strongbridge Biopharma

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge Biopharma plc (NasdaqGS: SBBP) to Xeris Pharmaceuticals, Inc. (NasdaqGS: XERS). Under the terms of the proposed transaction, shareholders of Strongbridge will receive only 0.7840 shares of Xeris plus one contingent value right for each share of Strongbridge that they own. KSF is seeking to determi

STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) and Strongbridge Biopharma plc is fair to Xeris shareholders. Upon closing, Xeris shareholders will exchange each share of Xerix common stock they own for 1 share of the combined company. Current Xeris shareholders are expected to own approximately 60% of the combined company. Halper Sadeh encourages Xeris shareholders to click here to

Xeris Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Xeris Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XERS

NEW YORK, May 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NASDAQ: SBBP) in connection with the Company's proposed merger with Xeris Pharmaceuticals, Inc. ("Xeris") (NASDAQ: XERS).  Under the terms of the merger agreement, Strongbridge shareholders will receive 0.7840 shares of Xeris common stock for each share of Strongbridge common stock that they own, representing implied per-share merger consideration of approximately $2.72 based upon Xeris' May 21, 2021 closing price of $3.47.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Strongbridge Biopharma plc

CHICAGO and DUBLIN and TREVOSE, Pa., May 24, 2021 /PRNewswire/ -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, and Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that they have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights ("CVRs").

Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

Xeris Pharmaceuticals Inc (NASDAQ: XERS) has agreed to acquire Strongbridge Biopharma plc (NASDAQ: SBBP) for stock and contingent value rights (CVRs), valuing Strongbridge at approximately $267 million. The transaction is expected to close early in the fourth quarter of 2021.

Strongbridge Shares Shoot Higher After Xeris' Buyout Deal At $267M

CHICAGO & DUBLIN & TREVOSE, Pa.--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, and Strongbridge Biopharma plc (“Strongbridge”) (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

Xeris Pharmaceuticals recently reported their Q1 earnings with a slight beat on EPS and revenue. Unfortunately, Xeris reported in the middle of the healthcare sell-off and XERS was unjustly punished.

Xeris Pharmaceuticals: Strong Growth In COVID-19 Headwinds Leads To Unjustified Sell-Off

Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q1 2021 Results - Earnings Call Transcript

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 3.23% and 6.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals (XERS) Reports Q1 Loss, Tops Revenue Estimates

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 66.29% year over year to ($0.30), which beat the estimate of ($0.34).

Xeris Pharmaceuticals: Q1 Earnings Insights

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced financial results for the first quarter 2021 and recent highlights. “We are very pleased with our steady, consistently growing financial performance in the first quarter notwithstanding the continued challenges created by the global pandemic. Demand fo

Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in following upcoming virtual events: The diaTribe Foundation Musings: Taking the Fear out of Hypoglycemia: Next-Generation Glucagon on May 13, 2021 RBC Capital Mar

Xeris Pharmaceuticals to Webcast Upcoming Presentations

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 13, 2021. Management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Com

Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an amendment to its existing loan and security agreement with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB). The amendment allows for extensions of interest-only payments for up to 12 months, subject t

Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank

Xeris Pharmaceuticals (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris Pharmaceuticals (XERS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CHICAGO & DUBLIN--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the United Kingdom's Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo® (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabet

Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Xeris and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553,398 shares of common stock, par value $0.0001 per share (the “Shares”), to funds managed by Deerfield Management Company, L.P., which are existing investors in the Company, at a purchas

News for Xeris Biopharma Holdings Stock (XERS)